Galena Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Galena Pharma's estimated annual revenue is currently $3.8M per year.
- Galena Pharma's estimated revenue per employee is $112,000
Employee Data
- Galena Pharma has 34 Employees.
- Galena Pharma grew their employee count by 36% last year.
Galena Pharma's People
| Name | Title | Email/Phone |
|---|
Galena Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $223.4M | 1116 | 5% | $65M | N/A |
#2 | $13.6M | 97 | 2% | $23.1M | N/A |
#3 | $1.1M | 13 | N/A | N/A | N/A |
#4 | $87.5M | 492 | -4% | $206M | N/A |
#5 | $41.9M | 272 | 18% | N/A | N/A |
#6 | $53.4M | 305 | 22% | N/A | N/A |
#7 | $55.8M | 314 | -5% | $102.6M | N/A |
#8 | $13.6M | 97 | 13% | N/A | N/A |
#9 | $0.2M | 3 | N/A | N/A | N/A |
#10 | $2.8M | 29 | N/A | N/A | N/A |
What Is Galena Pharma?
Galena Pharma Oy is a Finnish pharmaceutical factory specialising in contract manufacturing and packaging services. Our production facilities in Kuopio manufacture various products relating to health and well-being under contract: pharmaceuticals, medical devices, nutritional supplements, cosmetics, animal care products and sports products.
keywords:N/A
N/A
Total Funding
34
Number of Employees
$3.8M
Revenue (est)
36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Galena Pharma News
ImmunoBiology Ltd. Galena Biopharma. Table of Content: Market Definition and Overview; Research Method and Logic; Market Competition Analysis...
... Aop Orphan Pharmaceuticals AG, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Incyte Corp, Italfarmaco SpA, MEI Pharma Inc, PharmaEssentia Corp.
Galena Biopharma. Bavarian Nordic. Celldex Therapeutics. ImmunoCellular Therapeutics. Takeda. Spectrum Pharmaceuticals. GlaxoSmithKline.
Other Companies in Kuopio
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.8M | 50 | 0% | N/A |
#2 | $26.5M | 76 | 29% | N/A |
#3 | $16.8M | 80 | 25% | N/A |
#4 | $11.5M | 82 | 32% | N/A |
#5 | $17.3M | 86 | 34% | N/A |